Hisun Pharm Hangzhou Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for HISUN PHARM HANGZHOU, and what generic and branded alternatives to HISUN PHARM HANGZHOU drugs are available?
HISUN PHARM HANGZHOU has twenty-one approved drugs.
Drugs and US Patents for Hisun Pharm Hangzhou
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hisun Pharm Hangzhou | OLANZAPINE | olanzapine | TABLET, ORALLY DISINTEGRATING;ORAL | 206892-003 | Dec 31, 2020 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Hisun Pharm Hangzhou | IRBESARTAN | irbesartan | TABLET;ORAL | 206194-003 | Jun 14, 2016 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Hisun Pharm Hangzhou | DACTINOMYCIN | dactinomycin | INJECTABLE;INJECTION | 207232-001 | Jul 16, 2019 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.